NASDAQ:PLRX Pliant Therapeutics (PLRX) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free PLRX Stock Alerts $12.52 -0.08 (-0.63%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$12.49▼$12.8850-Day Range$12.19▼$17.2152-Week Range$12.00▼$30.85Volume243,870 shsAverage Volume382,347 shsMarket Capitalization$754.20 millionP/E RatioN/ADividend YieldN/APrice Target$49.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Pliant Therapeutics alerts: Email Address Pliant Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside291.4% Upside$49.00 Price TargetShort InterestBearish12.38% of Shares Sold ShortDividend StrengthN/ASustainability-0.73Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.77) to ($3.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.18 out of 5 starsMedical Sector323rd out of 909 stocksPharmaceutical Preparations Industry143rd out of 425 stocks 3.5 Analyst's Opinion Consensus RatingPliant Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePliant Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.38% of the outstanding shares of Pliant Therapeutics have been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 18.9, which indicates bearish sentiment.Change versus previous monthShort interest in Pliant Therapeutics has recently increased by 6.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPliant Therapeutics does not currently pay a dividend.Dividend GrowthPliant Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePliant Therapeutics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Pliant Therapeutics is -0.73. Previous Next 1.8 News and Social Media Coverage News SentimentPliant Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Pliant Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for PLRX on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat Follows11 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of Pliant Therapeutics is held by insiders.Percentage Held by Institutions97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pliant Therapeutics are expected to decrease in the coming year, from ($2.77) to ($3.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pliant Therapeutics is -4.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pliant Therapeutics is -4.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPliant Therapeutics has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Pliant Therapeutics Stock (NASDAQ:PLRX)Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Read More PLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLRX Stock News HeadlinesApril 20, 2024 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) Sets New 1-Year Low at $12.35April 17, 2024 | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from AnalystsApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 9, 2024 | investing.comPliant Therapeutics Inc (PLRX)April 2, 2024 | globenewswire.comPliant Therapeutics to Participate in Upcoming Investor EventsMarch 27, 2024 | globenewswire.comPliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International ConferenceMarch 17, 2024 | finance.yahoo.comPLRX Oct 2024 30.000 callMarch 16, 2024 | finance.yahoo.comPLRX Oct 2024 7.500 putApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 12, 2024 | finanznachrichten.dePliant Therapeutics, Inc.: Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary FibrosisMarch 12, 2024 | globenewswire.comPliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary FibrosisMarch 11, 2024 | finance.yahoo.comPLRX Jul 2024 20.000 callMarch 8, 2024 | markets.businessinsider.comPliant Therapeutics: Strong Buy Rating on Promising Pipeline and Solid FinancialsMarch 6, 2024 | ca.finance.yahoo.comPLRX Jul 2024 10.000 putFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pliant Therapeutics Amid Promising Drug Pipeline and Financial StabilityFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pliant Therapeutics on Promising Pipeline and Strong FinancialsFebruary 28, 2024 | markets.businessinsider.comPliant Therapeutics (PLRX) Receives a Buy from TD CowenFebruary 27, 2024 | globenewswire.comPliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial ResultsFebruary 26, 2024 | globenewswire.comPliant Therapeutics to Participate in Upcoming Investor ConferencesFebruary 23, 2024 | finance.yahoo.comPLRX Mar 2024 10.000 putFebruary 18, 2024 | morningstar.comPliant Therapeutics Inc Ordinary Shares PLRXFebruary 18, 2024 | finance.yahoo.comPLRX Mar 2024 25.000 callFebruary 8, 2024 | markets.businessinsider.comBuy Rating on Pliant Therapeutics: Positive Outlook on Bexotegrast Despite Investor ConcernsFebruary 7, 2024 | markets.businessinsider.comBuy Rating on Pliant Therapeutics: Promising IPF Drug Outlook Overcomes PSC ConcernsFebruary 6, 2024 | msn.comPliant Therapeutics Achieves Success in Liver Disease TrialFebruary 5, 2024 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To KnowFebruary 5, 2024 | msn.comWhy Is Liver Disease-Focused Pliant Therapeutics Stock Trading Lower Today?See More Headlines Receive PLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today4/23/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PLRX CUSIPN/A CIK1746473 Webpliantrx.com Phone650-481-6770FaxN/AEmployees158Year FoundedN/APrice Target and Rating Average Stock Price Target$49.00 High Stock Price Target$63.00 Low Stock Price Target$38.00 Potential Upside/Downside+291.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161,340,000.00 Net MarginsN/A Pretax Margin-10,211.14% Return on Equity-31.15% Return on Assets-29.00% Debt Debt-to-Equity Ratio0.02 Current Ratio17.72 Quick Ratio17.72 Sales & Book Value Annual Sales$1.58 million Price / Sales477.34 Cash FlowN/A Price / Cash FlowN/A Book Value$7.91 per share Price / Book1.58Miscellaneous Outstanding Shares60,240,000Free Float56,866,000Market Cap$754.20 million OptionableOptionable Beta1.12 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Bernard Coulie M.B.A. (Age 57)M.D., Ph.D., President, CEO & Director Comp: $1.06MDr. Keith Lamont Cummings M.B.A. (Age 47)M.D., Chief Financial Officer Comp: $662.34kMr. Mike Ouimette J.D. (Age 51)General Counsel & Corporate Secretary Comp: $591.05kMr. Johannes P. Hull (Age 49)Chief Business Officer Comp: $631.64kDr. Éric Lefebvre M.D. (Age 60)Chief Medical Officer Comp: $763.49kDr. Rik DerynckScientific Founder & Member of Scientific Advisory BoardMr. Dean Sheppard M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Bill DeGrado Ph.D.Scientific Founder & Member of Scientific Advisory BoardMr. Hal Chapman M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Craig D. MuirInterim Chief Technology OfficerMore ExecutivesKey CompetitorsArcturus TherapeuticsNASDAQ:ARCTOcular TherapeutixNASDAQ:OCULAurinia PharmaceuticalsNASDAQ:AUPHALX OncologyNASDAQ:ALXOLongboard PharmaceuticalsNASDAQ:LBPHView All CompetitorsInsiders & InstitutionsMass General Brigham IncBought 288,690 shares on 4/4/2024Ownership: 0.479%Great Point Partners LLCBought 68,000 shares on 2/15/2024Ownership: 3.044%Granahan Investment Management LLCBought 211,557 shares on 2/15/2024Ownership: 1.921%First Light Asset Management LLCBought 658,516 shares on 2/14/2024Ownership: 5.997%Rhenman & Partners Asset Management ABSold 217,894 shares on 2/13/2024Ownership: 0.188%View All Insider TransactionsView All Institutional Transactions PLRX Stock Analysis - Frequently Asked Questions Should I buy or sell Pliant Therapeutics stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PLRX shares. View PLRX analyst ratings or view top-rated stocks. What is Pliant Therapeutics' stock price target for 2024? 9 brokers have issued twelve-month price objectives for Pliant Therapeutics' shares. Their PLRX share price targets range from $38.00 to $63.00. On average, they expect the company's stock price to reach $49.00 in the next twelve months. This suggests a possible upside of 291.4% from the stock's current price. View analysts price targets for PLRX or view top-rated stocks among Wall Street analysts. How have PLRX shares performed in 2024? Pliant Therapeutics' stock was trading at $18.11 at the start of the year. Since then, PLRX stock has decreased by 30.9% and is now trading at $12.52. View the best growth stocks for 2024 here. When is Pliant Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our PLRX earnings forecast. How were Pliant Therapeutics' earnings last quarter? Pliant Therapeutics, Inc. (NASDAQ:PLRX) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by $0.06. The business earned $1.61 million during the quarter, compared to analysts' expectations of $2.50 million. What ETFs hold Pliant Therapeutics' stock? ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What other stocks do shareholders of Pliant Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN). When did Pliant Therapeutics IPO? Pliant Therapeutics (PLRX) raised $90 million in an IPO on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager. Who are Pliant Therapeutics' major shareholders? Pliant Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Mass General Brigham Inc (0.48%). Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Hans Hull, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette. View institutional ownership trends. How do I buy shares of Pliant Therapeutics? Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PLRX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
